Donanemab is one of the new “disease modifying” treatments for Alzheimer’s disease, which works by clearing the protein ...

One analysis published in the journal Neurology last year warned that the drugs may "compromise long-term brain health by accelerating brain atrophy ... "Lecanemab and donanemab are the first ...

even though treatment with donanemab was only continued until amyloid plaques in the brain were cleared. “The delay of disease progression over the course of the trial is significant and will ...

Donanemab has been hailed 'a new hope' in the ... About 40 per cent of patients who are treated with this class of drugs develop brain brain swelling and bleeding,' he said.

Donanemab works by removing a sticky protein, beta amyloid plaque, from the brain. Such plaque build-up is hypothesized to be a cause of Alzheimer's disease. Tau plaque is also thought to ...

Medscape Medical News, April 27, 2023 AAN 2023 Donanemab Bests Aducanumab in ... 2023 Anti-Amyloids Linked to Accelerated Brain Atrophy Anti-amyloids have been linked to accelerated brain atrophy ...

News, April 27, 2023 AAN 2023 Donanemab Bests Aducanumab in Head-to ... News, April 27, 2023 ARVO 2023 Minocycline Doesn't Slow Geographic Atrophy in AMD A potential drug for age-related macular ...